Exscientia

This UK-based biotech company, established in 2012, leverages artificial intelligence to expedite the process of designing molecules for clinical use. By integrating AI into its operations, it aims to accelerate the pace of drug discovery and development, potentially revolutionizing the pharmaceutical industry.